Clinical trials: Early Rectal Neoplasms, open to volunteers
Early Rectal Cancer, Stage I Rectal Cancer
RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer
This is a multi-site, prospective, non-randomized phase 2 study evaluating neoadjuvant botensilimab in combination with balstilimab for patients with microsatellite stable (MSS) / mismatch repair proficient (MMRp) early rectal…
- Conditions
- Early Rectal Cancer, Stage I Rectal Cancer, Microsatellite Stable Rectal Carcinoma
- Trial name
- RECTIFY-1 (NCT07735624)
- Testing
- Botensilimab, Balstilimab
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Dana-Farber Cancer Institute
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Early Low Rectal Cancer
SCRT Combined With CAPOX and PD-1/CTLA4 Antibody for Early-stage Low Rectal Cancer
The study evaluates the combination of immunotherapy of PD-1/ CTLA4 antibody and neoadjuvant short-course radiotherapy in early low rectal cancer.
- Trial name
- NCT07837362
- Testing
- Shor-course radiotherapy, PD-1/CTLA4 Antibody, Capecitabine
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Fudan University
Rectal Adenocarcinoma, Rectal Cancer
ctDNA-Informed Management of Early-Stage Rectal Cancer
This is a phase 2 pragmatic study to examine the utility of ctDNA-informed treatment management for participants with early-stage rectal cancer using the Signatera Genome assay.
- Conditions
- Rectal Adenocarcinoma, Rectal Cancer, Early-stage Rectal Cancer, Locally Advanced Rectal Adenocarcinoma
- Trial name
- ULTIMATE (NCT07209215)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of California, Davis
Colorectal Cancer, Early Onset Colorectal Cancer
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
An increase in early-onset colorectal cancers (eoCRC), defined as a CRC before 50 years, is confirmed globally. CRC pathogenesis has been associated with several risk factors (family history, germline pathogenic variants…
- Conditions
- Colorectal Cancer, Early Onset Colorectal Cancer, Diet Habit, Risk Reduction
- Trial name
- DEMETRA (NCT05732623)
- Testing
- Semi Quantitative Food Frequency Questionnaire (SQFFQ)
- Where
- 8 sites in United States, Finland and 4 more
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- San Raffaele University
Early Rectal Neoplasms
The Application of a Novel Endoluminal Robotic System for Colorectal Endoscopic Submucosal Dissection
Endoluminal surgery through natural orifices is an effective, "incisionless" treatment for benign lesions and early-stage cancers in the urinary tract and gastrointestinal (GI) tract.
- Trial name
- NCT07486180
- Testing
- Colorectal Endoscopic Submucosal Dissection (ESD) Using the Intilume Surgical System
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Chinese University of Hong Kong
Early Low Rectal Cancer
The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer
The study evaluates the combination of immunotherapy of PD-1 antibody and neoadjuvant short-course radiotherapy in early low rectal cancer.
- Trial name
- TORCH-E (NCT05555888)
- Testing
- PD-1 antibody, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Fudan University
Early Low Rectal Cancer
Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer
TORCH-E2 is a prospective, multicentre, randomized phase II trial. 134 low-lying early (T1-3b/N0-1M0, distance from anal verge ≤5cm) patients will be recruited and assigned to Group 1 and Group 2 (1:1).
- Trial name
- TORCH-E2 (NCT06462053)
- Testing
- Short-course radiotherapy, PD-1 antibody (Toripalimab), Long-course radiotherapy
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Fudan University